研究者詳細 - 廣畑　聡

論文 - 廣畑　聡

分割表示 194 件中 101 - 120 件目／全件表示 >>

Early eicosapentaenoic acid treatment after percutaneous coronary intervention reduces acute inflammatory responses and ventricular arrhythmias in patients with acute myocardial infarction: A randomized, controlled study 査読国際誌

Masayuki Doi, Kazumasa Nosaka, Toru Miyoshi, Mutsumi Iwamoto, Masahito Kajiya, Keisuke Okawa, Rie Nakayama, Wataru Takagi, Ko Takeda, Satoshi Hirohata, Hiroshi Ito

INTERNATIONAL JOURNAL OF CARDIOLOGY 176 ( 3 ) 577 - 582 2014年10月

記述言語：英語掲載種別：研究論文（学術雑誌）出版者・発行元：ELSEVIER IRELAND LTD

Objective: We examined whether early loading of eicosapenlaenoic acid (EPA) reduces clinical adverse events by 1 month, accompanied by a decrease in C-reactive protein (CRP) values in patients with acute myocardial infarction (MI).
Background: Acute MI triggers an inflammatory reaction, which plays an important role in myocardial injury. EPA could attenuate the inflammatory response.
Methods: This prospective, open-label, blinded endpoint, randomized trial consisted of 115 patients with acute MI. They were randomly assigned to the EPA group (57 patients) and the control group (58 patients). After percutaneous coronary intervention (PCI), 1800 mg/day of EPA was initiated within 24 h.The primary endpoint was composite events, including cardiac death, stroke, re-infarction, ventricular arrhythmias, and paroxysmal atrial fibrillation within 1 month.
Results: Administration of EPA significantly reduced the primary endpoint within 1 month (10.5 vs 29.3%, p = 0.01), especially the incidence of ventricular arrhythmias (7.0 vs 20.6%, p = 0.03). Peak CRP values after PCI in the EPA group were significantly lower than those in the control group (median [interquartile range], 8.2 [5.6-10.21 mg/dl vs 9.7 [7.6-13.91 mg/dl p < 0.01). Logistic regression analysis showed that EPA use was an independent factor related to ventricular arrhythmia until 1 month, with an odds ratio of 0.29 (95% confidence interval, 0.09 to 0.96, p = 0.04).
Conclusions: Early EPA treatment after PCI in the acute stage of MI reduces the incidence of ventricular arrhythmias, and lowers CRP values. (C) 2014 Elsevier Ireland Ltd. All rights reserved.

DOI： 10.1016/j.ijcard.2014.08.055

Low serum level of secreted frizzled-related protein 5, an anti-inflammatory adipokine, is associated with coronary artery disease 査読国際誌

Toru Miyoshi, Masayuki Doi, Shinichi Usui, Mutsumi Iwamoto, Masahito Kajiya, Ko Takeda, Kazumasa Nosaka, Rie Nakayama, Keisuke Okawa, Wataru Takagi, Kazufumi Nakamura, Satoshi Hirohata, Hiroshi Ito

ATHEROSCLEROSIS 233 ( 2 ) 454 - 459 2014年4月

記述言語：英語掲載種別：研究論文（学術雑誌）出版者・発行元：ELSEVIER IRELAND LTD

Objective: Secreted frizzled-related protein 5 (SFRP5) is an anti-inflammatory adipokine that is associated with insulin resistance in animals. To extend these observations to humans, we investigated the association of serum SFRP5 levels in subjects with and without coronary artery disease (CAD).
Methods: Subjects (n = 185, 68 + 11 years, 79% male) suspected of having CAD were enrolled in the study and were divided into two groups, CAD and non-CAD subjects, according to the results of their coronary angiographies. Serum SFRP5 levels of the subjects were measured by an enzyme-linked immunosorbent assay.
Results: The serum SFRP5 levels in the subjects with CAD were significantly lower than those in the non-CAD subjects (median [interquartile range]: 47.7 [26.6] vs. 52.4 [29.6] ng/mL, respectively; p = 0.02). The serum SFRP5 levels significantly correlated with body mass index, the homeostasis model of assessment of insulin resistance, adiponectin levels, and CAD severity. Multivariate logistic regression analysis revealed that a decreased serum SFRP5 level (log transformed) was independently associated with CAD for all subjects (adjusted odds ratio, 0.36; 95% confidence interval, 0.14-0.94; p = 0.03).
Conclusion: Serum SFRP5 levels are significantly associated with CAD in humans, suggesting that low SFRP5 levels may contribute to CAD. (C) 2014 Elsevier Ireland Ltd. All rights reserved.

DOI： 10.1016/j.atherosclerosis.2014.01.019

New Estimation Method of Total Creatine Phosphokinase Release in Early Stage in Acute Myocardial Infarction

Kitawaki T, Oka H, Usui S, Hirohata S, Kusachi S

International Journal of Cardiovascular and Cerebrovascular Disease 2 ( 2 ) 18 - 27 2014年

Serum adipocyte fatty acid-binding protein is independently associated with complex coronary lesions in patients with stable coronary artery disease

Masahito Kajiya, Toru Miyoshi, Masayuki Doi, Shinichi Usui, Mutsumi Iwamoto, Ko Takeda, Kazumasa Nosaka, Rie Nakayama, Satoshi Hirohata, Shozo Kusachi, Kazufumi Nakamura, Hiroshi Ito

HEART AND VESSELS 28 ( 6 ) 696 - 703 2013年11月

記述言語：英語掲載種別：研究論文（学術雑誌）出版者・発行元：SPRINGER

The association between circulating adipocyte fatty acid-binding protein (A-FABP) levels and coronary artery disease (CAD) is reported. We assessed whether plasma A-FABP levels are associated with angiographic coronary lesion morphology in patients with stable CAD. Serum A-FABP levels were analyzed in 115 patients with stable CAD (mean age 69 +/- 10 years; 80 % men). These patients were angiographically studied and divided into two groups: simple lesions (n = 34) and complex lesions (n = 81). We also compared 50 age- and gender-matched controls with no evidence of CAD. Serum A-FABP levels in patients with stable CAD were significantly higher than those in controls. In patients with stable CAD, serum A-FABP levels were significantly higher in patients with complex lesions than in those with simple lesions: median (25th-75th percentile), 23.4 (17.7-30.8) vs 18.2 (12.2-24.7) ng/ml, P < 0.01. Serum A-FABP levels were also significantly associated with angiographic scores of extent of coronary lesion (r = 0.21, P = 0.02). Multiple logistic analysis that included dyslipidemia, statin therapy, and extent score demonstrated that serum A-FABP was independently associated with complex lesions. The multiple adjusted odds ratio for a complex lesion with a serum A-FABP level (per doubling) was 2.38 (95 % confidence interval, 1.03-6.41; P = 0.03). High serum A-FABP levels were significantly associated with complex coronary lesions in patients with stable CAD, suggesting that high A-FABP levels may be involved in coronary plaque vulnerability.

DOI： 10.1007/s00380-012-0310-1

Adaptive-servo ventilation combined with deep sedation is an effective strategy during pulmonary vein isolation 国際誌

Takashi Murakami, Hirosuke Yamaji, Kenji Numa, Hiroshi Kawamura, Masaaki Murakami, Shunichi Higashiya, Shigeshi Kamikawa, Kazuyoshi Hina, Satoshi Hirohata, Shozo Kusachi

Europace 15 ( 7 ) 951 - 956 2013年7月

記述言語：英語掲載種別：研究論文（学術雑誌）出版者・発行元：OXFORD UNIV PRESS

AimsPulmonary vein isolation (PVI) by catheter ablation for atrial fibrillation (AF) requires suppression of patient restlessness by sufficient sedation in addition to maintaining stable respiration. We applied adaptive-servo ventilation (ASV) and examined the effects of ASV combined with deep propofol sedation on PVI using a NavX.Methods and resultsWe analysed 75 paroxysmal AF (PAF) patients (62 ± 11 years
53 men and 22 women) who underwent PVI for treatment of PAF using an ASV system combined with deep sedation (ASV group). Control patients included 75 consecutive PAF patients (62 ± 11 years
51 men and 24 women) who underwent PVI just before introduction of the ASV system. Deep sedation was defined as a Ramsay sedation score of 6. The ASV group had a lower frequency of restless body movements compared with the control group during PVI (1.5 ± 0.7 vs. 7.8 ± 1.4 times, P &lt
0.01). The frequency of respiratory compensation and EnGuide alignment of catheter position by the NavX was lower in the ASV (4.2 ± 3.3 and 8.8 ± 7.1 times) than control group (7.1 ± 5.1 and 15.2 ± 10.0 times, P &lt
0.05 and &lt
0.01, respectively). Consequently, significantly lower total electrical energy supply (48.7 ± 6.0 KJ) was required in the ASV than control group (64.5 ± 24.9 KJ, P &lt
0.01). Further, significantly shorter fluoroscopy and procedural times were observed in the ASV (28 ± 5 and 109 ± 25 min) than the control group (33 ± 6 and 141 ± 38 min, respectively, P &lt
0.01) and the AF recurrence rate was significantly lower in the ASV than the control group (12 vs. 25%, P &lt
0.01).ConclusionASV combined with deep sedation is an effective strategy during PVI using the NavX in patients with PAF. © 2013 The Author.

DOI： 10.1093/europace/eut007

A potential association between the number of CA repeats in the promoter region of the ADAMTS9 gene with lymphatic metastasis of breast cancer

Mikdat Bozer, Fatma Asik, Muradiye Acar, Hacer Haltas, Sibel Yenidunya, Metin Canbal, Vehap Topcu, Muhammet Ramazan Yigitoglu, Mehmet Gunduz, Esra Gunduz, Satoshi Hirohata, Kadir Demircan

TURKISH JOURNAL OF MEDICAL SCIENCES 43 ( 5 ) 671 - 677 2013年

記述言語：英語掲載種別：研究論文（学術雑誌）出版者・発行元：TUBITAK SCIENTIFIC & TECHNICAL RESEARCH COUNCIL TURKEY

Aim: We investigated the effect of the number of cytosine-adenine (CA) repeats in the ADAMTS9 promoter region on breast cancer lymphatic metastasis.Materials and methods: Thirty-one postoperative breast cancer patients were selected and examined retrospectively. The patients were classified into 2 groups: metastatic or nonmetastatic. Thirty healthy women were selected as the control group, and their peripheral blood was obtained. Following DNA isolation from the cancer tissue specimens and peripheral blood, the promoter region of the ADAMTS9 gene was directly sequenced and the number of CA repeats was determined.Results: The number of CA repeats ranged between 19 and 21 in the control and metastatic groups. However, in the nonmetastatic group, the number of CA repeats ranged between 17 and 18. This difference in the median number of CA repeats between the control group and the nonmetastatic group was statistically significant.Conclusion: A potential relationship may exist between lymphatic metastasis in breast cancer and the number of CA repeats in the promoter region of the ADAMTS9 gene. Our study indicates a potential association between the number of CA microsatellite repeats in the promoter region of the ADAMTS9 gene and breast cancer lymphatic metastasis.

DOI： 10.3906/sag-1210-84

Web of Science

Scopus

researchmap

ADAMTSの機能

廣畑聡

血管新生研究の最先端 208 - 216 2013年

Usefulness of Dabigatran Etexilate as Periprocedural Anticoagulation Therapy for Atrial Fibrillation Ablation 国際誌

Hirosuke Yamaji, Takashi Murakami, Kazuyoshi Hina, Shunichi Higashiya, Hiroshi Kawamura, Masaaki Murakami, Shigeshi Kamikawa, Satoshi Hirohata, Shozo Kusachi

CLINICAL DRUG INVESTIGATION 33 ( 6 ) 409 - 418 2013年

記述言語：英語掲載種別：研究論文（学術雑誌）出版者・発行元：ADIS INT LTD

The usefulness of dabigatran etexilate for the prevention of stroke in patients with atrial fibrillation (AF) has been reported.
In this study the efficacy and safety of dabigatran etexilate for anticoagulation for AF ablation were examined.
Patients were divided into three groups: Group 1, interrupted warfarin bridged by heparin between pre- and post-ablation; Group 2, continuous warfarin therapy; and Group 3, dabigatran etexilate therapy. Anticoagulation therapy with warfarin or dabigatran etexilate was performed from 30 days before to at least 90 days after AF ablation. Dabigatran etexilate was administered at 110 or 150 mg twice daily, depending on renal function and age.
Patients' clinical characteristics, associated disorders, echocardiographic parameters and arrhythmia status were not different among the three groups. Procedural parameters such as procedural time and radiofrequency energy supply were also not different among the three groups. The dabigatran etexilate group and the warfarin groups had no embolic complications (stroke, cerebral transient ischaemic attack, deep venous thrombosis or pulmonary embolism). No pericardial tamponade was observed in the dabigatran etexilate group, while two patients in each of Group 1 (2/194, 1.0 %) and Group 2 (2/203, 0.98 %) developed cardiac tamponade, though the differences were not significant. Pericardial effusion and groin haematoma were observed in one patient each (1/105, 0.9 %) in the dabigatran etexilate group, and the incidences were not different from the warfarin group (Group 1: 4/194, 2.1 % and 2/194, 1.0 %; Group 2: 3/203, 1.5 % and 2/203, 1.0 %, respectively). As a whole, the safety outcomes did not differ among the three groups.
Dabigatran etexilate is an effective and safe anticoagulation therapy for AF ablation. Thus, dabigatran etexilate appears to be useful as an alternative anticoagulant therapy to warfarin for AF ablation.

DOI： 10.1007/s40261-013-0081-1

Reduced Diurnal Variation of Heart Rate is Associated With Increased Plasma B-Type Natriuretic Peptide Level in Patients With Atrial Fibrillation 国際誌

Kamikawa S, Miyoshi T, Doi M, Orita N, Sangawa M, Nakatsu T, Noguchi Y, Hirohata S, Kusachi S, Nakamura K, Ito H

Clinical Cardiology 36 ( 7 ) 394 - 400 2013年

Cyclic tensile strain inhibits interleukin-1 beta and tumor ncerosis factor-alpha-induced aggrecanase in human chondrosarcoma cell line OUMS-27 by stretch-activated channles

Takashi Ohtsuki, Keiichiro Nishida, Satoshi Hirohata, Yoshifumi Ninomiya

GLYCOBIOLOGY 22 ( 11 ) 1582 - 1583 2012年11月

The tumor growth inhibitory effect of ADAMTS1 is accompanied by the inhibition of tumor angiogenesis

Satoshi Hirohata, Takashi Ohtsuki, Masanari Obika, Hiroko Ogawa, Shozo Kusachi, Yoshifumi Ninomiya

GLYCOBIOLOGY 22 ( 11 ) 1559 - 1559 2012年11月

Impact of MDA-LDL/LDL-C and AA/EPA ratio to plaque vulnerability in patients with stable angina pectoris

Hiroaki Otsuka, Masayuki Ueeda, Takuro Masuda, Yasunori Arai, Daisuke Yamada, Nobuhiko Ohnishi, Atsushi Takaishi, Satoshi Hirohata, Shozo Kusachi, Hiroshi Ito

CIRCULATION 125 ( 19 ) E697 - E697 2012年5月

Elevated serum adipocyte fatty acid-binding protein concentrations are independently associated with renal dysfunction in patients with stable angina pectoris 国際誌

Mutsumi Iwamoto, Toru Miyoshi, Masayuki Doi, Ko Takeda, Masahito Kajiya, Kazumasa Nosaka, Rie Nakayama, Satoshi Hirohata, Shinichi Usui, Shozo Kusachi, Kosuke Sakane, Kazuhfumi Nakamura, Hiroshi Ito

CARDIOVASCULAR DIABETOLOGY 11 ( 26 ) 26 - 26 2012年3月

記述言語：英語掲載種別：研究論文（学術雑誌）出版者・発行元：BMC

Background: Chronic kidney disease (CKD) is associated with cardiovascular events. Adipocyte fatty acid-binding protein (A-FABP) plays an important role in atherosclerosis. We investigated whether plasma A-FABP is involved in renal function in patients with stable angina pectoris.
Methods: A total of 221 patients with significant coronary artery stenosis were enrolled after coronary angiography. CKD was defined as an estimated glomerular filtration rate (eGFR) < 60 ml/min/1.73 m(2). The severity of coronary stenosis was assessed using a modified Gensini score and coronary angiography. Serum A-FABP levels were determined by enzyme-linked immunosorbent assay.
Results: Serum A-FABP levels were significantly correlated with both eGFR (r = -0.41, p < 0.01) and the severity of coronary artery stenosis (r = 0.16, p = 0.02), and these relationships remained significant after adjusting for confounding factors. The prevalence of CKD and multi-vessel disease was significantly higher among patients with serum A-FABP levels above the median value of 20.3 ng/ml than among patients with serum A-FABP levels below the median value (57% vs. 27%, p < 0.01 and 64% vs. 48%, p = 0.02, respectively). Multivariate analysis revealed that the presence of three-vessel disease in comparison with single-vessel disease was independently associated with the higher A-FABP (per doubling) (odds ratio; 2.26, 95% confidential interval; 1.28-3.98, p < 0.01) and tended to be associated with the lower eGFR (p = 0.06).
Conclusion: Serum A-FABP may have a significant role in the interplay between renal dysfunction and coronary atherosclerosis.

DOI： 10.1186/1475-2840-11-26

Sufficient pulmonary vein image quality of non-enhanced multi-detector row computed tomography for pulmonary vein isolation by catheter ablation 国際誌

Hirosuke Yamaji, Kazuyoshi Hina, Hiroshi Kawamura, Takashi Murakami, Masaaki Murakami, Satoshi Hirohata, Natsuki Ohmaru, Shozo Kusachi

EUROPACE 14 ( 1 ) 52 - 59 2012年1月

記述言語：英語掲載種別：研究論文（学術雑誌）出版者・発行元：OXFORD UNIV PRESS

Aims We evaluated the quality of non-enhanced multi-detector row computed tomography (MDCT) images of the pulmonary vein (PV) and the clinical results of catheter ablation to isolate the PV for treatment of atrial fibrillation (AF) without the use of contrast medium in patients with chronic kidney disease (CKD).
Methods and results We compared PV images quantitatively and qualitatively between non-enhanced and enhanced images (n = 50). Procedural parameters and clinical outcomes were compared between catheter ablation for AF referring solely to non-enhanced MDCT in CKD patients (n = 20) and using enhanced MDCT images integrated with electroanatomic mapping in non-CKD patients (n = 30). In gross anatomy, complete agreement was obtained between non-enhanced and enhanced MDCT images. Bland-Altman plots and cumulative coefficient variation showed good agreement in PV diameter determination between non-enhanced and enhanced MDCT images. There were no statistically significant differences in procedural or fluoroscopic times between PV isolation only referring to non-enhanced MDCT images and that using enhanced MDCT images integrated with electroanatomic mapping. Similarly, the ablation success rate and AF-free status at 3 months after PV isolation did not differ between PV isolation referring only to non-enhanced MDCT images and that using an electroanatomic integration system. No complications occurred in PV isolation with or without enhanced MDCT.
Conclusions Non-enhanced MDCT provides adequate PV image quality both quantitatively and qualitatively. The present study suggests that catheter ablation referring solely to non-enhanced MDCT images for AF could be performed with clinically acceptable results. These findings warrant further studies involving a much larger number of patients to confirm the present results.

DOI： 10.1093/europace/eur284

Serum hepatitis B virus DNA before liver transplantation correlates with HBV reinfection rate even under successful low-dose hepatitis B immunoglobulin prophylaxis 査読国際誌

Tetsuya Yasunaka, Akinobu Takaki, Takahito Yagi, Yoshiaki Iwasaki, Hiroshi Sadamori, Kazuko Koike, Satoshi Hirohata, Masashi Tatsukawa, Daisuke Kawai, Hidenori Shiraha, Yasuhiro Miyake, Fusao Ikeda, Haruhiko Kobashi, Hiroaki Matsuda, Susumu Shinoura, Ryuichi Yoshida, Daisuke Satoh, Masashi Utsumi, Teppei Onishi, Kazuhide Yamamoto

HEPATOLOGY INTERNATIONAL 5 ( 4 ) 918 - 926 2011年12月

記述言語：英語掲載種別：研究論文（学術雑誌）出版者・発行元：SPRINGER

Purpose The combination of hepatitis B immunoglobulin (HBIg) and nucleos(t)ide analogues has been accepted as the best treatment to control hepatitis B recurrence after orthotopic liver transplantation (OLT). However, the optimal dose of HBIg remains unclear. We have previously reported that high-dose HBIg in the early period followed by low-dose HBIg with nucleos(t)ide analogues offers reliable and cost-effective control of hepatitis B recurrence. The aim of this study was to investigate intrahepatic hepatitis B virus (HBV) reinfection status with our clinically successful protocol.
Methods We quantified levels of intrahepatic HBV covalently closed circular (ccc) deoxyribonucleic acid (DNA) and serum hepatitis B core-related antigen (HBcrAg), a new serological marker that can estimate intrahepatic cccDNA levels. Nucleos(t)ide analogues were administered in all cases.
Results No patients showed recurrence of hepatitis B surface antigen (HBsAg) or HBV-DNA. However, HBV, cccDNA, and HBcrAg were positive in 57% and 48% of patients after OLT, respectively. Pre-OLT serum HBV-DNA and HBcrAg levels correlated linearly with post-OLT cccDNA levels (r = 0.534, P < 0.05, and r = 0.634, P < 0.05, respectively). High serum HBV-DNA and HBcrAg levels, particularly with > 3 log(10) copies/mL and > 4 log(10) IU/mL, respectively, at the time of OLT, were associated with high levels of post-OLT cccDNA. Even with our successful protocol, nearly half of patients showed HBV reinfection.
Conclusions Patients with high serum HBV-DNA and HBcrAg levels before OLT (particularly > 3 log(10) copies/mL and > 4 log(10) IU/mL, respectively) should be followed with care for HBV recurrence.

DOI： 10.1007/s12072-011-9265-z

Residual Diastolic Cross-Bridge and Decreased Expression of Energy Metabolism Genes in Hypertrophied Rat Hearts Induced by Chronic beta-Adrenergic Stimulation

Kazufumi Nakamura, Daiji Miura, Juichiro Shimizu, Toru Miyoshi, Hiroko Toyota, Hiroshi Okuyama, Wakako Yoshikawa, Satoshi Akagi, Kunihisa Kohno, Masahi Yoshida, Hiroshi Morita, Satoshi Hirohata, Kengo Kusano, Tatsuhito Matsuo, Naoto Yagi, Hirhoshi Ito

CIRCULATION 124 ( 21 ) 2011年11月

ADAMTS1 Play Roles In Endothelial Cell Apoptosis

Satoshi Hirohata, Masanari Obika, Faruk Hatipoglu, Kunihiko Hatanaka, Toru Miyoshi, Hiroko Ogawa, Kaori Sakamoto, Mehmet Z. Cilek, Junko Inagaki, Hiroshi Ito, Shozo Kusachi, Yoshifumi Ninomiya

CIRCULATION 124 ( 21 ) 2011年11月

非糖性糖尿病性未治療高血圧患者におけるUACRの分布とhigh-normalの頻度

小川弘子, 大丸奈月, 中津高明, 泉礼司, 間島圭一, 土岐美沙子, 小林亜紗子, 廣畑聡, 池田敏, 草地省蔵

臨床病理 59 ( 補冊 ) 115 - 115 2011年10月

虚血性心疾患患者によるCAVIと冠動脈動脈硬化、左心機能の関連性の検討

小川弘子, 三好亨, 土井正行, 廣畑聡, 草地省蔵, 小出典男

臨床病理 59 ( 補冊 ) 220 - 220 2011年10月

発作性心房細動の出現率に対するarterial stiffness増加の影響

小川弘子, 三好亨, 土井正行, 廣畑聡, 草地省蔵, 小出典男

臨床病理 59 ( 補冊 ) 220 - 220 2011年10月

　前のページ - 次のページ　

<廣畑 聡>

論文 - 廣畑 聡

<廣畑　聡>

論文 - 廣畑　聡